1478O - Results of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) metastatic to the brain

L.Q Chow,F Barlesi,E.M Bertino,M.J Van Den Bent,H Wakelee,P.Y Wen,C.-H Chiu,S Orlov,M Majem,R Chiari,M Mckeage,C.-J Yu,F.K Hurtado,P Cazorla Arratia,Y Song,F Branle,M Shi,D.-W Kim

doi:10.1093/annonc/mdz260

1478O - Results of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) metastatic to the brain

L.Q Chow, F Barlesi + Show 16 more

Open Access

https://doi.org/10.1093/annonc/mdz260

Copy DOI

Journal: Annals of Oncology	Publication Date: Oct 1, 2019
Citations: 38	License type: elsevier-specific: oa user license

Affiliation: University of Washington, The Ohio State University Wexner Medical Center, Stanford University, University of Auckland, National Taiwan University Hospital, Seoul National University Hospital

#Research Grant #Part-time Employment + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

1478O - Results of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) metastatic to the brain

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.